•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Some investors have watched their healthcare stock holdings decline in value recently or over longer periods, but have remained invested because several companies continue to pay dividends with meaningful yields. For shareholders waiting for a sector recovery, dividend payments can help support total return potential.
Medtronic, Sanofi, and Bristol Myers Squibb all pay dividends with respectable yields, despite different stock performance trends. Depending on when investors first bought shares, they may still be in a position of being down on the investment while waiting for improvement in healthcare stocks.
Medtronic’s shares were down on the day, with a current price of $83.32. Key market data included a market capitalization of $107 billion and a dividend yield of 3.41%.
The company’s profitability has faced pressure. Gross margin fell from 66.6% in Q3 2025 to 64.9% in Q3 2026, while operating margin and net income also declined over the same period.
As shareholders wait for Medtronic to navigate the turbulent period and for the stock price to rebound, the company pays a dividend yielding 3.3%. Medtronic has also increased its dividend payout for 48 consecutive years.
Sanofi develops and manufactures treatments across oncology, neurology, and immunology. While the company has a broad portfolio and a large pipeline, it has struggled to reward shareholders, including in 2026 and over the last five years.
One key concern is the risk that Sanofi will eventually lose patent protection for Dupixent, a major contributor to results. Dupixent sales rose 32.2% in 2025 and generated €4.2 billion in revenue.
Sanofi will need its pipeline to offset future sales losses. The company has also faced leadership turbulence, with its board announcing in February that it was bringing in a new CEO.
Sanofi’s dividend yield is not specified in the provided figures, but the article notes that the company is paying a meaningful dividend yield while investors wait for progress.
Bristol Myers Squibb shares were described as up on the year, but still down about 10% over the last five years. One concern highlighted is slowing revenue from the company’s “legacy portfolio,” which declined from $25.7 billion in 2024 to $21.8 billion in 2025.
Additional risks include the patent cliff for Eliquis. Eliquis generated $14.4 billion in global revenue in 2025, but faces a future loss of exclusivity. The company may also add debt if it proceeds with a potential $1.5 billion acquisition of Orbital Therapeutics.
While investors wait for growth from Bristol’s pipeline to continue, the company pays a dividend yielding 4.2%. Of the three companies discussed, the article characterizes Bristol Myers Squibb as the strongest investment consideration due to stock momentum in 2026, while emphasizing that all three are paying dividends that can contribute to total return.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
